{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:11:32Z","timestamp":1785507092073,"version":"3.56.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.kint.2026.06.011","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:22:24Z","timestamp":1785316944000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Triple therapy is not required for all newly diagnosed cases of lupus nephritis"],"prefix":"10.1016","author":[{"given":"Julia","family":"Lichtnekert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-2956","authenticated-orcid":false,"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.06.011_bib1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.06.011_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.06.011_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.011_bib4","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.06.011_bib5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.011_bib6","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1093\/rheumatology\/keab126","article-title":"Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study","volume":"60","author":"Lu\u00eds","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2026.06.011_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ndt\/gfaf168","article-title":"How to interpret the number needed to treat for clinicians","volume":"41","author":"Chesnaye","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.06.011_bib12","unstructured":"A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology\/Renal Pathology Society (ISN\/RPS) 2003 Class III or IV Lupus Nephritis (LUNAR). ClinicalTrials.gov Identifier: NCT00282347. Updated January 16, 2015. Accessed July 8, 2026. https:\/\/clinicaltrials.gov\/study\/NCT00282347"},{"key":"10.1016\/j.kint.2026.06.011_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.06.011_bib9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/ndt\/gfaf033","article-title":"Disease-modifying anti-nephropathic drugs (DMANDs)-a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA)","volume":"40","author":"Teng","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.06.011_bib10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/ndt\/gfac304","article-title":"The influence of repeated flares in response to therapy and prognosis in lupus nephritis","volume":"38","author":"Perez-Arias","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.06.011_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:24:12Z","timestamp":1785439452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826005077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":12,"alternative-id":["S0085253826005077"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.011","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple therapy is not required for all newly diagnosed cases of lupus nephritis","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.07.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}